EGFR and non-small cell lung carcinoma: While the discovery of EGFR activating mutations and their correlation to gefitinib treatment response led to the compound being approved for the treatment of NSCLC with activating TK EGFR mutations in the EU in 2009, it was only in 2015 that gefitinib returned to the U.S. market [16,17,23,74].